Compugen To Receive $10 Mln Payment After Dosing First Patient In AstraZeneca's ARTEMIDE-Bil01 Trial
(RTTNews) - Cancer immunotherapy company Compugen Ltd. (CGEN) announced Monday that Compugen is entitled to receive a $10 million milestone payment from British drug major AstraZeneca (AZN), after the first patient was dosed in AstraZeneca's ARTEMIDE-Bil01 trial with rilvegostomig.
Rilvegostomig is a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical-stage anti-TIGIT antibody, COM902.
The ARTEMIDE-Bil01 trial is expected to recruit about 750 subjects in more than 20 countries with biliary tract cancer who will be randomized to receive rilvegostomig or placebo with investigator choice chemotherapy as adjuvant treatment after resection with curative intent.
read more
Amgen's Bkemv Approved As First Interchangeable Biosimilar To Soliris
The U.S. Food and Drug Administration has approved Amgen Inc.'s Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab), developed by British drug major AstraZeneca's Rare Disease unit Alexion Pharmaceuticals, to treat certain rare diseases. Soliris is a medicine used to treat adults and children with paroxysmal nocturnal haemoglobinuria or PNH...
RTTNews
|
il y a 211
Amazon, Microsoft, Pfizer To Invest Billions In French Projects
Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews
|
il y a 228
AstraZeneca To Withdraw Its Covid-19 Vaccine Vaxzevria Worldwide
AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...
RTTNews
|
il y a 233
AstraZeneca Says AIRSUPRA Now Commercially Available In US As FDA-approved Option For Asthma
AstraZeneca (AZN, AZN.L) announces Monday that AIRSUPRA (albuterol/budesonide) is now commercially available in the US by prescription. AIRSUPRA was approved based on the results from two Phase III trials, MANDALA and DENALI.
RTTNews
|
il y a 340
Allorion Therapeutic Inks Agreement With AstraZeneca For EGFR L858R Allosteric Inhibitor Program
Allorion Therapeutics, a US and China-based biotechnology company, on Tuesday entered into an exclusive option and global license agreement with British drug major AstraZeneca plc (AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC).
RTTNews
|
il y a 360
Gilead Sciences, Compugen Ink Up To $848 Mln Deal For Pre-clinical Antibody Program
Gilead Sciences, Inc. (GILD) announced Tuesday an agreement with Holon, Israel-based cancer immunotherapy company Compugen Ltd. (CGEN) to exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate.
RTTNews
|
il y a 374
AstraZeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases
AstraZeneca plc (AZN) said Friday it has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA) to help protect access to medicines for cancer and rare disease patients.
RTTNews
|
il y a 490
AstraZeneca Q2 Profit Surges, Signs Gene Therapy Deal With Pfizer; Stock Up
Shares of AstraZeneca Plc were gaining around 4 percent in London trading as well as around 5 percent in pre-market activity on Nasdaq after the British drug major reported Friday significantly higher profit for its second quarter. Top line beat market estimates. Further, the company maintained its outlook for fiscal 2023, expecting growth. In addition, AstraZeneca noted that its Rare Disease ...
RTTNews
|
il y a 518
